Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
    • Media
  1. Home
  2. Investors

Press releases

24.10.2018

DEINOVE to collaborate with CALIBR to explore broadly the anti-infectious potentials of its bacterial collection

CALIBR is a division of the Scripps Research, a California non-profit corporation, dedicated to finding new treatments addressing unmet...
02.10.2018

Strategic partnership between DEINOVE and SOLVAY for the marketing of phytoene in North America and Asia

Solvay Novecare will market Phytoene as a cosmetic active ingredient in North America and Asia under the name ReGeN-oPhyt® This agreement...
28.09.2018

Deinove is the regional winner of the ‘PME Bougeons-nous’ awards in the ‘creative business’ category

The “PME Bougeons-nous” awards, organized by RMC, is the leading SME contest in France; DEINOVE was selected as the regional winner of the...
27.09.2018

2018 half-year consolidated results: strengthened financial situation, substantial progress in both areas of business

Cash position: +€9.9m at June 30, 2018 compared to +€4.9m at December 31, 2017 thanks to the reinforcement of shareholders' equity Half-...
13.09.2018

Strategic partnership between DEINOVE and UNIVAR for the distribution of Phyt-N-Resist® in the EMEA zone

UNIVAR will distribute the Phyt-N-Resist ® cosmetic active ingredient in the EMEA zone; UNIVAR is a world leader in the distribution of...
09.07.2018

Deinove awarded by the bioeconomy community

DEINOVE won the “Most Innovative Technology” award, with PHYT-N-RESIST ® , during the nnual meeting point for IAR cluster members. is the...
28.06.2018

Deinove enters into collaboration with bioMérieux to discover new antibiotics

bioMérieux will provide DEINOVE with more than 250 strains (130 species) for screening of antibiotic and antifungal activities. This...
19.06.2018

Arrowhead initiates coverage on Deinove in the United States

The American financial services and research provider firm has initiated coverage on Deinove’s stock with a valuation of up to €5.55 per...
15.06.2018

DEINOVE: Successful capital increase of € 8.5 million

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...
14.06.2018

DEINOVE announces today the launch of a capital increase through an accelerated book building

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...
  • « first
  • ‹ previous
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • next ›
  • last »

Investors

  • Corporate governance
    • Board of Directors
    • Executive Committee
  • DEINOVE Shares
  • Financial Calendar
  • Documentation Center
    • Financial Reports
    • Investors slide deck
    • Analyst Coverage
    • Number of Shares and Voting Rights
    • Newsletter to Shareholders
    • Shareholders' Meetings
    • Declaration of transactions performed on company securities
    • Liquidity Agreement
    • Public offerings - Documentation
    • Bonds Convertible into Shares (OCA)
  • Press releases
  • Investor relations
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

    

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home